Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
by
Walmsley, Sharon
, Klein, Marina B.
, Harris, Marianne
, Wobeser, Wendy
, McClymont, Elisabeth
, Lee, Marette
, Coutlée, François
, Raboud, Janet
, Trottier, Sylvie
, Lipsky, Nancy
, Smaill, Fiona
, Money, Deborah
, Yudin, Mark H.
, Loutfy, Mona
, Cohen, Jeffrey
in
Adolescent
/ Adult
/ Aged
/ Antibodies, Viral
/ ARTICLES AND COMMENTARIES
/ CD4 Lymphocyte Count
/ Female
/ HIV Infections - complications
/ Humans
/ Middle Aged
/ Papillomavirus Infections - prevention & control
/ Papillomavirus Vaccines - immunology
/ Vaccination
/ Viral Load
/ Young Adult
2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
by
Walmsley, Sharon
, Klein, Marina B.
, Harris, Marianne
, Wobeser, Wendy
, McClymont, Elisabeth
, Lee, Marette
, Coutlée, François
, Raboud, Janet
, Trottier, Sylvie
, Lipsky, Nancy
, Smaill, Fiona
, Money, Deborah
, Yudin, Mark H.
, Loutfy, Mona
, Cohen, Jeffrey
in
Adolescent
/ Adult
/ Aged
/ Antibodies, Viral
/ ARTICLES AND COMMENTARIES
/ CD4 Lymphocyte Count
/ Female
/ HIV Infections - complications
/ Humans
/ Middle Aged
/ Papillomavirus Infections - prevention & control
/ Papillomavirus Vaccines - immunology
/ Vaccination
/ Viral Load
/ Young Adult
2019
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
by
Walmsley, Sharon
, Klein, Marina B.
, Harris, Marianne
, Wobeser, Wendy
, McClymont, Elisabeth
, Lee, Marette
, Coutlée, François
, Raboud, Janet
, Trottier, Sylvie
, Lipsky, Nancy
, Smaill, Fiona
, Money, Deborah
, Yudin, Mark H.
, Loutfy, Mona
, Cohen, Jeffrey
in
Adolescent
/ Adult
/ Aged
/ Antibodies, Viral
/ ARTICLES AND COMMENTARIES
/ CD4 Lymphocyte Count
/ Female
/ HIV Infections - complications
/ Humans
/ Middle Aged
/ Papillomavirus Infections - prevention & control
/ Papillomavirus Vaccines - immunology
/ Vaccination
/ Viral Load
/ Young Adult
2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
Journal Article
The Efficacy of the Quadrivalent Human Papillomavirus Vaccine in Girls and Women Living With Human Immunodeficiency Virus
2019
Request Book From Autostore
and Choose the Collection Method
Overview
Abstract
Background
Human papillomavirus (HPV) vaccination is safe and efficacious in women without human immunodeficiency virus (HIV). Although good immunogenicity has been observed in women living with HIV (WLWH), efficacy data in this population are needed.
Methods
We enrolled 420 females aged ≥9 years (range, 9–65) living with HIV. Participants were to receive 3 doses of qHPV vaccine (0/2/6 months). The main endpoint was vaccine failure (ie, incident persistent qHPV infection, cervical intraepithelial neoplasia of grade 2 or higher [CIN2+], or genital warts). We compared these rates to published rates in vaccinated and unvaccinated women without HIV as well as unvaccinated WLWH.
Results
Among 279 eligible women, median follow-up was 2 years. In the intention-to-treat population, the incidence rate (IR) of persistent qHPV (HPV6/11/16/18) was 2.3 per 100 person-years (/100PY) (95% confidence interval [CI], 1.1–4.1), and IR of genital warts was 2.3/100PY (95% CI, 1.2–4.1). In the per-protocol efficacy population, IR of persistent qHPV was 1.0/100PY (95% CI, 0.3–2.6) and of genital warts was 1.0/100PY (95% CI, 0.3–2.5). No cases of CIN2+ occurred. Reported rates of qHPV-related infection and disease within vaccinated women without HIV, unvaccinated women without HIV, and vaccinated WLWH: 0.1 (95% CI, 0.02–0.03), 1.5 (95% CI, 1.1–2.0), and 1.2 (95% CI, 0.2–3.4) /100PY, respectively. The rate of persistent qHPV among vaccinated WLWH was lower than among unvaccinated WLWH (2.3 vs 6.0/100PY).
Conclusions
Vaccinated WLWH may be at higher risk for vaccine failure than vaccinated women without HIV. However, overall rates of vaccine failure were low, and rates of persistent qHPV were lower than in unvaccinated WLWH.
Vaccinated women living with Human Immunodeficiency Virus (HIV) may be at higher risk for vaccine failure than vaccinated women without HIV. However, overall vaccine failure rates were low and rates of persistent vaccine-type HPV were lower than in unvaccinated women living with HIV.
Publisher
Oxford University Press
Subject
This website uses cookies to ensure you get the best experience on our website.